XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix Arm Compared To Placebo, With Markedly Fewer Events In Specific Categories Of Adverse Events During That Time
Portfolio Pulse from Benzinga Newsdesk
XBiotech announced that the primary endpoint for its Phase 2 study was to assess the safety and tolerability of Natrunix when used with the ON+5FU+LV combination. The study found fewer adverse events in the Natrunix arm compared to the placebo, with significantly fewer events in specific categories during the 24-week treatment period.
June 18, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
XBiotech's Phase 2 study of Natrunix demonstrated fewer adverse events compared to placebo, indicating positive safety and tolerability results. This could boost investor confidence and positively impact the stock price in the short term.
The positive results from the Phase 2 study of Natrunix, showing fewer adverse events compared to placebo, suggest that the drug is safer and more tolerable. This is likely to increase investor confidence and could lead to a short-term increase in XBiotech's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100